Clinical trial
Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate…
NCT00310674 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00310674 |
|---|---|
| Title | Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age |
| Official title | A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant… |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Vaccines Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prevention of Meningococcal Infection |
| Intervention type | Biological |
| Interventions | Meningococcal C Conjugate Vaccine |
| Enrollment | 150 |
| Start date | Sep 1, 2004 |
| First posted | Apr 4, 2006 |
| Last update posted | Mar 13, 2007 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: